Trial Profile
Phase II study of Gemcitabine plus alternate-day administrations of S-1 in patients with unresectable advanced pancreatic cancer.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 May 2016
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Gimeracil/oteracil/tegafur (Primary)
- Indications Adenosquamous carcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 25 Feb 2013 New trial record